87 related articles for article (PubMed ID: 24726246)
1. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?
Jit M; Choi YH; Laprise JF; Boily MC; Drolet M; Brisson M
Vaccine; 2014 May; 32(26):3237-42. PubMed ID: 24726246
[TBL] [Abstract][Full Text] [Related]
2. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
[TBL] [Abstract][Full Text] [Related]
3. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
4. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
5. Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model.
Shafer LA; Jeffrey I; Elias B; Shearer B; Canfell K; Kliewer E
Vaccine; 2013 Oct; 31(42):4848-55. PubMed ID: 23933332
[TBL] [Abstract][Full Text] [Related]
6. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
7. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
8. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
10. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
11. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?
Günther OP; Ogilvie G; Naus M; Young E; Patrick DM; Dobson S; Duval B; Noël PA; Marra F; Miller D; Brunham RC; Pourbohloul B
J Infect Dis; 2008 Jun; 197(12):1653-61. PubMed ID: 18513154
[TBL] [Abstract][Full Text] [Related]
12. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
14. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
15. Mothers' screening histories influence daughters' vaccination uptake: an analysis of linked cervical screening and human papillomavirus vaccination records in the North West of England.
Spencer Nee Pilkington AM; Brabin L; Verma A; Roberts SA
Eur J Cancer; 2013 Apr; 49(6):1264-72. PubMed ID: 23290788
[TBL] [Abstract][Full Text] [Related]
16. Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era.
de Blasio BF; Neilson AR; Klemp M; Skjeldestad FE
J Public Health (Oxf); 2012 Dec; 34(4):539-47. PubMed ID: 22707556
[TBL] [Abstract][Full Text] [Related]
17. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
18. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
19. [Vaccines against human papillomavirus (HPV); between registration and implementation].
van Rossum TG; de Melker HE; Houweling H; Voordouw AC; Meijer CJ; Helmerhorst TJ; Kretzschmar M; Berkhof J; van der Noordaa J
Ned Tijdschr Geneeskd; 2008 Apr; 152(17):987-92. PubMed ID: 18549172
[TBL] [Abstract][Full Text] [Related]
20. [Developments in HPV vaccination].
de Melker H; Kenter G; van Rossum T; Conyn-van Spaendonck M
Ned Tijdschr Geneeskd; 2012; 156(47):A5410. PubMed ID: 23171565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]